PNU-282,987 je lek koji deluje kao potentan i selektivan agonist za α7 podtip neuronskih nikotinskih acetilholinskih receptora.[1][2] U životinjskim studijama, on ispoljava nootropne efekte, te njegovi derivati mogu da budu korisni u tretmanu šizofrenije.[3][4] PNU-282,987 nije podesan za kliničku upotrebu zbog jake inhibicije hERGantimete.[5]
^Bodnar, A.; Cortes-Burgos, L.; Cook, K.; Dinh, D.; Groppi, V.; Hajos, M.; Higdon, N.; Hoffmann, W.; Hurst, R. (2005). „Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors”. Journal of Medicinal Chemistry. 48 (4): 905—908. PMID15715459. doi:10.1021/jm049363q.
^Hansen, H.; Timmermann, D.; Peters, D.; Walters, C.; Damaj, M.; Mikkelsen, J. (2007). „Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics”. Journal of neuroscience research. 85 (8): 1810—1818. PMID17455307. doi:10.1002/jnr.21293.
^Redrobe, J. (2009). "Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice". European journal of pharmacology 602 (1): 58–65. . PMID18848931. doi:10.1016/j.ejphar.2008.09.035.Недостаје или је празан параметар |title= (помоћ)
^Walker, DP; Wishka, DG; Piotrowski, DW; et al. (2006). „Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists”. Bioorg. Med. Chem. 14 (24): 8219—48. PMID17011782. doi:10.1016/j.bmc.2006.09.019.CS1 одржавање: Експлицитна употреба et al. (веза)
